


## Oxotremorine sesquifumarate

Cat. No.:	HY-101239
CAS No.:	17360-35-9
Molecular Formula:	C <sub>16</sub> H <sub>22</sub> N <sub>2</sub> O <sub>5</sub>
Molecular Weight:	380.4
Target:	mAChR
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (328.60 mM; Need ultrasonic)						
	H <sub>2</sub> O : 100 mg/mL (262.88 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.6288 mL	13.1441 mL	26.2881 mL
				5 mM	0.5258 mL	2.6288 mL	5.2576 mL
10 mM				0.2629 mL	1.3144 mL	2.6288 mL	
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.57 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.47 mM); Clear solution						

### BIOLOGICAL ACTIVITY

Description	Oxotremorine sesquifumarate is a mAChR agonist that mainly activates M2 receptors. Oxotremorine sesquifumarate can be used for neurological research <sup>[1][2]</sup> .
In Vitro	Oxotremorine (10.5 μM) produces a paralytic effect on twitch responses of rat diaphragm in vitro to direct and indirect stimulation <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	In rats with sciatic nerve injuries, Oxotremorine (10, 5, 2.1 μg; 10 μL) i.t. dose-dependently suppresses the tactile

---

hypersensitivity<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. M Das, D K Ganguly, et al. Enhancement by oxotremorine of acetylcholine release from the rat phrenic nerve. *Br J Pharmacol.* 1978 Feb;62(2):195-8.

[2]. Zhiyang Song, et al. Muscarinic receptor activation potentiates the effect of spinal cord stimulation on pain-related behavior in rats with mononeuropathy. *Neurosci Lett.* 2008 May 2;436(1):7-12.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA